BioCentury
ARTICLE | Company News

Lilly licenses Aduro’s STING inhibitors

December 19, 2018 2:11 AM UTC

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases.

Aduro will receive $12 million up front and be eligible for up to $620 million in development and commercial milestones per product, plus single to low double-digit royalties. The company will have an option to co-fund the clinical development of each product in exchange for an increase in royalty payments. ...